

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BATTISTINI et al.

Appln. No. 10/812,308

Filed: March 20, 2004

Confirmation No. 1799

Atty. Ref.: 4865-38

T.C. / Art Unit: 1614

Examiner: C.E. Rae

FOR: USE OF (3-(2-ETHYLPHENYL)-5-METHOXYPHENYL)-1H-[1,2,4]-TRIAZOLE FOR  
THE TREATMENT OF AUTOIMMUNE DISEASES

\* \* \*

**AMENDMENT UNDER 37 CFR § 1.116**

October 6, 2007

**Mail Stop AF**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 6, 2007, entry and consideration of the following amendments and remarks are respectfully requested.

An amendment to the **specification** is presented on page 2.

The priority claim is withdrawn and support for the claimed invention is added.

The **claims** are presented on page 3.

**Remarks** begin on page 4.